What Codebreaker Labs does

Codebreaker Labs is a Boulder, Colorado-based private biotechnology company founded in 2025 that builds causal genomics data by experimentally mapping genetic variants to cellular effects. The company combines high-throughput DNA synthesis, next-generation CRISPR technologies (including the proprietary MAD7, Onyx, and STAR-CRISPR platforms pioneered by the founding team) and single-cell assays to generate the Codex of Variant Profiles, a continuously expanding dataset of experimentally validated variant effects on human cell behavior built from tens of thousands of parallel-programmed variants and tens of millions of single-cell phenotypic fingerprints.

The company operates a platform-plus-modules architecture. The core asset is the Codex of Variant Profiles, which serves as training and ground-truthing data for the company's AI. Layered on top is Arlington AI, a clinical decision support system that integrates patient WGS/WES data with the Codex and proprietary predictive AI to interpret variants of unknown significance by placing them in context of biologically validated neighbors. The product suite also includes the BioData-as-a-Service Platform for custom variant mapping and a prototype Data Explorer visualization interface, with the INSIGHTS analytical module listed as forthcoming.

Codebreaker generates revenue through subscription/recurring enterprise relationships. The Codex Pioneers Program, an invitation-based channel, targets leading hospitals with early access to Arlington AI and the Codex, priority support, pilot access, and co-publication rights. Biopharma partners access custom variant mapping through the BioData-as-a-Service Platform. Pricing is not publicly disclosed and is structured through bespoke collaboration agreements. The company has raised approximately $4.48M in a single funding round on 2026-08-26 and operates with 1-10 employees.

Name

Codebreaker Labs

Legal name

Codebreaker Labs

Website

https://codebreakerlabs.io

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Codebreaker Labs is a Boulder-based biotech founded in 2025 that builds causal genomics data by experimentally mapping genetic variants to cellular effects. It sells the Codex of Variant Profiles dataset, Arlington AI clinical decision support, and custom variant-mapping services to hospitals and biopharma partners.

Ownership category

akta.pro rank

Product category

Genomics Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq) (HLAAAIAG)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Causal genomics
• Variant interpretation
• Clinical decision support
• Functional genomics data
• Genomic data platform

Headquarters

HQ city

Boulder

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. BioData-as-a-Service Platform: Custom variant mapping collaborations providing access to proprietary causal genomics data and experimental capabilities for biopharma and research partners.
2. Arlington AI Clinical Decision Support Software: Clinical decision support system for WGS and WES interpretation, enabling faster and more accurate rare variant case analysis for healthcare providers.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Codebreaker Labs builds causal genomics data by experimentally mapping genetic variants to cellular effects at scale, using high-throughput DNA synthesis, next-generation CRISPR technologies, and single-cell assays. The company sells the Codex of Variant Profiles, a continuously expanding dataset of experimentally validated variant effects, the Arlington AI clinical decision support software for rare variant interpretation, and a bioData-as-a-Service platform for custom variant mapping collaborations with biopharma partners.

Product overview

Codebreaker Labs offers a platform-plus-modules architecture centered on its proprietary Codex of Variant Profiles—the world's largest dataset of causal variant effects on human cell behavior. The core platform combines bioData-as-a-Service for custom variant mapping collaborations with Arlington AI, a clinical decision support software that integrates patient genomic data with the Codex and predictive AI for variant interpretation. The Arlington AI suite includes the main CDS software and the forthcoming INSIGHTS module, with a Data Explorer prototype feature demonstrating visualization capabilities.

Differentiator

Problem solved

Functional benefit

Brands

• Arlington AI: Clinical Decision Support Software system that integrates patient genomic data with Codex of Variant Profiles and proprietary predictive AI for faster, more accurate interpretation of rare and challenging cases.
• Codex of Variant Profiles
• bioData-as-a-Service Platform
• Codex Pioneers Program

Products and services

• Codex of Variant Profiles A continuously expanding library of experimentally validated variant effects on human cell behavior, generated through high-throughput DNA synthesis and single-cell assays. The dataset serves as the foundational resource for training and ground-truthing AI models for variant interpretation.
• Arlington AI Clinical Decision Support Software A next-generation clinical decision support system that integrates patient genomic data (WGS/WES) with the Codex of Variant Profiles and proprietary predictive AI to enable faster, more accurate interpretation of rare and challenging clinical cases, including variants that elude expert review.
• bioData-as-a-Service Platform Custom variant mapping collaborations enabling partners to leverage Codebreaker's synthetic biology platform for generating proprietary variant effect data tailored to specific research or clinical needs.

Quantifiable outcome

• Reduces interpretation time from months/years to faster clinical insights for rare and challenging genomic cases

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

Partnerships

Two partnerships are on record, tiered core.

• Codex Pioneers Partner HospitalscoreStrategic or Co-development PartnerThe Codex Pioneers Program invites leading hospitals to partner with Codebreaker for early access to the Arlington AI platform and Codex of Variant Profiles. Partners gain the opportunity to nominate high-priority variants for functional mapping, receive priority support and pilot access, and participate in co-publications. This represents a strategic co-development relationship focused on transforming genomic uncertainty into clinical clarity.
• Biopharma PartnerscoreStrategic or Co-development PartnerCodebreaker has established successful collaborations with leading biopharma partners through Artisan Biosciences, including a five-year period of productive partnerships. These collaborations focus on custom variant mapping and biological ground truth data generation for therapeutic development applications.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Inscripta: Co-founded by CEO Ryan T. Gill, Inscripta developed commercial-scale CRISPR-based genome engineering platforms (including the Onyx platform). It is the most direct technology ancestor to Codebreaker's Codex pipeline and shares the same founders and core wet-lab approach.
• Artisan Biosciences: Also co-founded by Gill and Warnecke-Gill, Artisan operated a five-year biopharma services business doing custom genome-engineering collaborations. Codebreaker's BioData-as-a-Service Platform is effectively an extension of Artisan's biopharma services model applied to functional variant mapping.
• Deep Genomics: AI-driven company focused on identifying novel therapeutic targets and interpreting genetic variation for drug discovery. Directly comparable as an AI-for-genomics platform competing for biopharma R&D budgets and emphasizing computational interpretation of variants.

Broad incumbents

• Recursion Pharmaceuticals: Large-scale AI-for-biology platform combining high-throughput experimental data generation with machine learning. Comparable in spirit (wet-lab + AI loop generating proprietary biological data) but operates at much larger scale across broader indication areas rather than focusing specifically on variant interpretation.
• Insitro: Machine learning-driven drug discovery company that generates proprietary experimental datasets (e.g., induced pluripotent stem cell-derived data) to train models. Shares the 'generate biological ground truth data to train AI' philosophy, though focused on phenotypic screens for therapeutics rather than variant effects.
• Tempus Labs: Established leader in clinical genomics and AI-driven precision medicine, offering NGS testing and clinical decision support tools to hospitals and oncologists. Directly comparable as a buyer of hospital clinical genomics interpretation capacity and as a competitor in CDS software for variant analysis.
• Foundation Medicine: Major clinical genomics company (Roche subsidiary) providing comprehensive genomic profiling and clinical decision support for oncology. Comparable as a hospital-facing platform that interprets variants at scale and could either compete with or partner around Arlington AI.
• Invitae: Clinical genetic testing company providing WES/WGS and variant interpretation services to clinicians. Overlaps with Codebreaker's hospital customer base and competes for the same clinical genomics interpretation budget.

Emerging players

• Owkin: AI-for-healthcare company building models on multimodal patient and biological data, including genomic data, with biopharma and hospital customers. Comparable as an emerging AI-for-clinical-genomics player with a similar biopharma + hospital dual GTM.
• Function Biosciences: Emerging functional genomics company using high-throughput experimental assays to map variant function at scale, often targeting biopharma partners. Direct overlap in 'wet-lab functional genomics at scale for AI training data' thesis, though at an earlier stage and smaller scale than Codebreaker's claimed Codex pipeline.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Codebreaker Labs